Plus, news about Benchling, Invivyd, Immuneering, Scilex and Sana Biotechnology:
📉 Sarepta’s debt refinancing: The biotech, which went through a complicated exchange with the FDA this summer over the safety of its Duchenne gene therapy ...
↧